ArticleKidney research and clinical practice2017
Rapid deterioration of preexisting renal insufficiency after autologous mesenchymal stem cell therapy.
Article in Kidney research and clinical practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Translating Mesenchymal Stem Cell Research into Chronic Kidney Disease Therapy: A Systematic and Clinical Review.Iranian biomedical journal · 2026Pooled it
- CRISPR-mediated engineering of mesenchymal stromal/stem cells: a summary of recent progress in immunological applications for regenerative medicine and cancer therapy.Stem cell research & therapy · 2025Review
- Intra-ovarian injection of autologous menstrual blood-derived-mesenchymal stromal cells: a safe and promising method to improve pregnancy rate in poor ovarian responders.Stem cell research & therapy · 2025Observational
- Human Umbilical Cord-Mesenchymal Stem Cells Combined With Low Dosage Nintedanib Rather Than Using Alone Mitigates Pulmonary Fibrosis in Mice.Stem cells international · 2025Article
- Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Mesenchymal stem cell therapy in diabetic foot ulcer: An updated comprehensive review.Health science reports · 2024Article
- Neuroinflammation mechanism underlying neuropathic pain: the role of mesenchymal stem cell in neuroglia.AIMS neuroscience · 2024Review
- Innovative preconditioning strategies for improving the therapeutic efficacy of extracellular vesicles derived from mesenchymal stem cells in gastrointestinal diseases.Inflammopharmacology · 2023Review
- Chronic Kidney Disease: Challenges in Translational Medicine.Methods in molecular biology (Clifton, N.J.) · 2023Review
- Adverse events, side effects and complications in mesenchymal stromal cell-based therapies.Stem cell investigation · 2022Review
- Stem cells in the treatment of renal fibrosis: a review of preclinical and clinical studies of renal fibrosis pathogenesis.Stem cell research & therapy · 2021Review
- Potential of Exosomes as Cell-Free Therapy in Articular Cartilage Regeneration: A Review.International journal of nanomedicine · 2021Review
- Current understanding of the administration of mesenchymal stem cells in acute kidney injury to chronic kidney disease transition: a review with a focus on preclinical models.Stem cell research & therapy · 2019Review
- The Pros and Cons of Mesenchymal Stem Cell-Based Therapies.Cell transplantation · 2019Review
- Adipose tissue-derived mesenchymal stromal cells for treating chronic kidney disease: A pilot study assessing safety and clinical feasibility.Kidney research and clinical practice · 2019Article
- Use of mesenchymal stem cells for chronic kidney disease.Kidney research and clinical practice · 2019Article
- Extracellular vesicles in renal physiology and clinical applications for renal disease.The Korean journal of internal medicine · 2019Review
- Mesenchymal Stem Cells in Renal Fibrosis: The Flame of Cytotherapy.Stem cells international · 2019Review
- Concise Reviews: Stem Cells and Kidney Regeneration: An Update.Stem cells translational medicine · 2019Review
- Capillary rarefaction from the kidney point of view.Clinical kidney journal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Administration of autologous mesenchymal stem cells (MSCs) has been shown to improve renal function and histological findings in acute kidney injury (AKI) models. However, its effects in chronic kidney disease (CKD) are unclear, particularly in the clinical setting. Here, we report our experience with a CKD patient who was treated by intravenous infusion of autologous MSCs derived from adipose tissue in an unknown clinic outside of Korea. The renal function of the patient had been stable for several years before MSC administration. One week after the autologous MSC infusion, the preexisting renal insufficiency was rapidly aggravated without any other evidence of AKI. Hemodialysis was started 3 months after MSC administration. Renal biopsy findings at dialysis showed severe interstitial fibrosis and inflammatory cell infiltration, with a few cells expressing CD34 and CD117, 2 surface markers of stem cells. This case highlights the potential nephrotoxicity of autologous MSC therapy in CKD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.